San Francisco, February 17, 2020 – Recardio Inc., a clinical stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Patient recruitment continues at all participating centers.
Read MoreRecardio at J.P. Morgan Conference 2020
San Francisco, January 13, 2020 – Recardio Inc., a clinical-stage life science company focusing on therapies for cardiovascular diseases, was participating in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
Read MoreClosing of Series B Financing Round
San Francisco, December 13th, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases,announced the closing of its Series B financing round.
Read MoreRecardio’s Digital Platform CardioCare Rolled Out in Europe
San Francisco, November 6th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its it has rolled out its digital platform CardioCare throughout Europe to support its future clinical development programs in cardiovascular.
Read MoreRecardio at BIO Europe 2019
San Francisco, October 15, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced that it was presenting at the BIO Europe in Hamburg.
Read More- 1
- 2
- 3
- …
- 5
- Next Page »